MX2016010871A - Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18. - Google Patents

Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18.

Info

Publication number
MX2016010871A
MX2016010871A MX2016010871A MX2016010871A MX2016010871A MX 2016010871 A MX2016010871 A MX 2016010871A MX 2016010871 A MX2016010871 A MX 2016010871A MX 2016010871 A MX2016010871 A MX 2016010871A MX 2016010871 A MX2016010871 A MX 2016010871A
Authority
MX
Mexico
Prior art keywords
dosing regimen
fgf
weeks
compound dosing
new dosing
Prior art date
Application number
MX2016010871A
Other languages
English (en)
Inventor
Christoph H Ladel
Guehring Hans
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2016010871A publication Critical patent/MX2016010871A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente invención proporciona un nuevo régimen de dosificación para la administración de FGF18 en el tratamiento de un trastorno del cartílago tal como, por ejemplo, la osteoartritis o la lesión del cartílago; se proporciona específicamente un plan de tratamiento preferido que comprende administraciones cada 3 semanas o cada 5 semanas de un compuesto de FGF-18 por ciclo de tratamiento; el nuevo régimen de dosificación puede incluir la co-administración de un fármaco anti-inflamatorio.
MX2016010871A 2014-02-20 2015-02-20 Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18. MX2016010871A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14000600 2014-02-20
PCT/EP2015/053624 WO2015124727A1 (en) 2014-02-20 2015-02-20 Fgf-18 compound dosing regimen

Publications (1)

Publication Number Publication Date
MX2016010871A true MX2016010871A (es) 2016-11-17

Family

ID=50151088

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016010872A MX2016010872A (es) 2014-02-20 2015-02-20 Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18.
MX2016010871A MX2016010871A (es) 2014-02-20 2015-02-20 Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016010872A MX2016010872A (es) 2014-02-20 2015-02-20 Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18.

Country Status (25)

Country Link
US (2) US9889179B2 (es)
EP (2) EP3119417B1 (es)
JP (2) JP6431083B2 (es)
KR (2) KR102410988B1 (es)
CN (2) CN106456713A (es)
AR (2) AR099558A1 (es)
AU (2) AU2015220773B2 (es)
BR (2) BR112016018696A2 (es)
CA (2) CA2938793A1 (es)
DK (2) DK3107559T3 (es)
ES (2) ES2688551T3 (es)
HR (2) HRP20181572T1 (es)
HU (1) HUE040350T2 (es)
IL (2) IL247084B (es)
LT (2) LT3107559T (es)
MX (2) MX2016010872A (es)
NZ (2) NZ723148A (es)
PL (2) PL3119417T3 (es)
PT (2) PT3119417T (es)
RS (2) RS57709B1 (es)
RU (2) RU2691946C2 (es)
SG (2) SG11201606505UA (es)
SI (2) SI3119417T1 (es)
WO (2) WO2015124731A1 (es)
ZA (2) ZA201605548B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015124739A1 (en) 2014-02-20 2015-08-27 Merck Patent Gmbh Implant comprising fgf-18
SG11201606505UA (en) 2014-02-20 2016-09-29 Merck Patent Gmbh Fgf-18 compound dosing regimen
SI3419625T1 (sl) 2016-02-22 2021-08-31 Novartis Ag Postopki za uporabo agonistov FXR
CN111164429A (zh) * 2017-09-29 2020-05-15 默克专利有限公司 预测对fgf-18化合物反应性的炎性生物标志物
WO2020161341A1 (en) * 2019-02-08 2020-08-13 Merck Patent Gmbh Treatment of patients at risk of rapid progression of osteoarthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136970A1 (en) * 2002-10-07 2004-07-15 Ellsworth Jeff L. Methods for administering FGF18
EP1896053B1 (en) * 2004-07-06 2018-10-31 ZymoGenetics, Inc. Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use
EP1978997A1 (en) * 2005-12-22 2008-10-15 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
ES2392883T3 (es) * 2006-08-25 2012-12-14 Ares Trading S.A. Tratamiento de trastornos de cartílagos con FGF-18
JP5815206B2 (ja) * 2006-08-25 2015-11-17 アレス トレーディング ソシエテ アノニム Ｆｇｆ−１８を用いた軟骨障害の治療
DE102006043260A1 (de) * 2006-09-11 2008-03-27 Krones Ag Etikettieranlage
EP2688890B1 (en) * 2011-03-22 2017-08-30 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
AU2015220781B2 (en) 2014-02-20 2018-05-24 Merck Patent Gmbh FGF-18 in graft transplantation and tissue engineering procedures
WO2015124739A1 (en) 2014-02-20 2015-08-27 Merck Patent Gmbh Implant comprising fgf-18
SG11201606505UA (en) 2014-02-20 2016-09-29 Merck Patent Gmbh Fgf-18 compound dosing regimen

Also Published As

Publication number Publication date
RU2700582C2 (ru) 2019-09-18
PL3119417T3 (pl) 2019-01-31
ES2688551T3 (es) 2018-11-05
HRP20181570T1 (hr) 2018-11-30
LT3107559T (lt) 2018-10-25
ES2689071T3 (es) 2018-11-08
CN106456713A (zh) 2017-02-22
IL247083A0 (en) 2016-09-29
JP2017512194A (ja) 2017-05-18
WO2015124731A1 (en) 2015-08-27
MX2016010872A (es) 2016-11-17
RS57853B1 (sr) 2018-12-31
AR099510A1 (es) 2016-07-27
RU2016137289A3 (es) 2018-10-19
EP3107559A1 (en) 2016-12-28
JP2017507142A (ja) 2017-03-16
US20170072017A1 (en) 2017-03-16
RU2016137292A3 (es) 2018-09-17
AU2015220777B2 (en) 2020-10-22
JP6431082B2 (ja) 2018-11-28
EP3119417A1 (en) 2017-01-25
SI3119417T1 (sl) 2018-11-30
LT3119417T (lt) 2018-10-25
CA2938793A1 (en) 2015-08-27
RU2691946C2 (ru) 2019-06-19
AU2015220773A1 (en) 2016-09-01
RU2016137292A (ru) 2018-03-21
EP3119417B1 (en) 2018-07-11
ZA201605548B (en) 2018-12-19
KR20160116001A (ko) 2016-10-06
AU2015220777A1 (en) 2016-09-01
CA2938791A1 (en) 2015-08-27
SG11201606505UA (en) 2016-09-29
IL247084A0 (en) 2016-09-29
IL247083B (en) 2019-09-26
BR112016018696A2 (pt) 2017-10-17
EP3107559B1 (en) 2018-07-11
BR112016018685A2 (pt) 2017-10-17
ZA201605547B (en) 2019-09-25
US9889179B2 (en) 2018-02-13
HRP20181572T1 (hr) 2018-11-30
JP6431083B2 (ja) 2018-11-28
RS57709B1 (sr) 2018-12-31
SI3107559T1 (sl) 2018-11-30
PT3119417T (pt) 2018-10-31
WO2015124727A1 (en) 2015-08-27
DK3107559T3 (en) 2018-10-15
US9724388B2 (en) 2017-08-08
AR099558A1 (es) 2016-08-03
NZ723148A (en) 2022-08-26
IL247084B (en) 2019-09-26
US20170056474A1 (en) 2017-03-02
KR20160116000A (ko) 2016-10-06
KR102410988B1 (ko) 2022-06-17
NZ723139A (en) 2022-12-23
AU2015220773B2 (en) 2020-10-08
PL3107559T3 (pl) 2019-01-31
SG11201606502YA (en) 2016-09-29
DK3119417T3 (en) 2018-10-22
KR102410986B1 (ko) 2022-06-17
CN106232622A (zh) 2016-12-14
PT3107559T (pt) 2018-10-31
RU2016137289A (ru) 2018-03-21
HUE040350T2 (hu) 2019-03-28

Similar Documents

Publication Publication Date Title
TW201613859A (en) Analogs of PRIDOPIDINE, their preparation and use
SA517390583B1 (ar) مشتقات حمض أميني جديدة، عملية لتحضيرها وتركيبات صيدلية تحتوي عليها
EA201890126A1 (ru) Новые бициклические производные, способ их получения и фармацевтические композиции, содержащие их
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
GEP201706686B (en) Novel pyrrole compounds, preparation method thereof, and pharmaceutical compositions containing them
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
MX2016010871A (es) Regimen de dosificacion del compuesto de factor de crecimiento de fibroblastos 18.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
MX2020009444A (es) Composicion farmaceutica oral de isotretinoina con dosis baja y su proceso de preparacion.
MA40313A (fr) Composition pharmaceutique à base d'isotrétinoïne destinée à la voie orale
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
MX2016010877A (es) Amidas antimitoticas para el tratamiento del cancer y desordenes proliferativos.
GEP20186893B (en) Pyrazines modulators of gpr6
EA201691741A1 (ru) Фармацевтическая композиция
MX2018015269A (es) Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos.
IT201700026139A1 (it) Dispositivo dosatore per l'alimentazione di un prodotto da infusione.
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
HRP20181123T1 (hr) Spojevi 3,4-diamino-6-kloropirazin-2-karboksamida za liječenje bolesti posredovanih s enac
UA100842U (ru) Лекарственная композиция для тумесцентной анестезии
GB201521377D0 (en) Direct valveless reaction volatile compounder "D.V.R.V.C"
MX2016001219A (es) Nuevos complejos de agomelatina y de acidos sulfonicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG Grant or registration